Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 29, 2016
Pharmacy Choice - News - Over-the-Counter Drugs - July 29, 2016

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 16 of 16     Go To Page:

7/29/16 - Diet Doc Announces New Prescription Diet Pills as Part of Their Safe and Effective Weight Loss Programs
By a News Reporter-Staff News Editor at Health& Medicine Week Diet Doc announces a unique, prescription diet pill as part of the diet programs. Diet Doc's Medical Director, Dr. Rao cautions those seeking to buy bootleg, online diet pills. Dr. Rao, medical director of Diet Doc issues caution to those seeking to buy online prescriptions or diet pil
7/29/16 - Galderma Announces FDA Approval of Full Prescription-Strength Differin Gel For Over-the-Counter Acne Use
By a News Reporter-Staff News Editor at Drug Week Galderma, a global leader focused on medical solutions in skin health, announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration for Differin Gel as an over-the-counter treatment for acne. It also marks the first new, FDA- approved
7/28/16 - AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
AbbVie, a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or nave to proteasome inhibitors and have received one to thr
7/28/16 - BRISTOL MYERS SQUIBB CO - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our revenues increased by 13% for the six months ended June 30, 2016 as a result of higher Opdivo, Eliquis and Daklinza product sales. These impacts were partially offset by the expiration of U.S. commercialization rights to Abilify*, the transfer of Erbitux* rights in North America and increased competition for Reyataz, Baraclude and Sustiva in ce
7/28/16 - Eyeon Therapeutics Out-Licenses Proprietary OTC Dry Eye Product
The agreement was executed in May and is the latest step in commercializing this polymer technology developed at Particles Sciences, a Lubrizol Advanced Materials, Inc. LifeSciences Group company and a leading drug delivery CDMO. David Kleinman, MD, CEO of Eyeon Therapeutics commented, "We are grateful to Particle Sciences for their support in help
7/28/16 - Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
Sanofi announced today that the U.S. Food and Drug Administration approved Adlyxin TM, a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. "The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people livin
7/28/16 - Teva Agrees to Divest 79 Pharma Products to Settle Actavis Generics Merger Issues [Daily Star, The (Lebanon)]
Teva Pharmaceutical Industries Ltd. has agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges that its proposed $40.5 billion acquisition of Allergan plcs generic pharmaceutical business would be anticompetitive. The FTC order will preserve competition in U.S. pharmaceutical markets where Teva and Allergan
7/27/16 - Consumer Reports Finds Harmful Dietary Supplement Ingredients Widely Accessible to Consumers
With the help of an expert group of independent physicians and dietary supplement researchers, Consumer Reports identified 15 supplement ingredients currently on the market that are potentially harmful, with risks including organ damage, cancer and cardiac arrest. And supplement products don't need to be approved by the Food and Drug Administration
7/27/16 - Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes
Sanofi Receives FDA Approval of Adlyxin (TM) for Treatment of Adults with Type 2 Diabetes- Adlyxin (TM) is approved as Lyxumia in more than 60 countries- Paris, France- July 28, 2016- Sanofi announced today that the U.S. Food and Drug Administration approved Adlyxin (TM), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunc
7/26/16 - Allergan Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Release date- 25072016- DUBLIN- Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for TRUBERZI in the European Union. 'With this positive decision for TRUBERZI, Allergan is one step closer to bringing this innovative medication to IBS-D patie
7/26/16 - Tests show the SPF on many sunscreens is lower than advertised [Chattanooga Times Free Press, Tenn.]
Consumer Reports named names Banana Boat Kids Tear-Free Sting- Free Lotion SPF 50 and CVS Kids Sun Lotion SPF 50 each had an actual SPF of 8.. Americans might be shocked to learn that the Food and Drug Administration views sunscreen as an over-the-counter drug that must be regulated and tested. Yet the FDA does not test sunscreens.
7/25/16 - AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR? (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved a New Drug Application for VIEKIRA XR? extended-release tablets. "AbbVie's work continues to contribute to the transformation of hepatitis C care through our focus on evolving our current therapies as part of our ongoing commitme
7/25/16 - Allergan Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for TRUBERZI in the European Union. 4 TRUBERZI is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea in adults. 1 In two pivotal trials, TRUB
7/25/16 - Enanta Announces the U.S. Food and Drug Administration has approved AbbVie's New, Once-Daily VIEKIRA XR? (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration has approved AbbVie s New Drug Application for VIEKIRA XR? extended release tablets. Our collaborative partner
7/25/16 - Flamel Technologies to Report Second Quarter 2016 Results
Release date- 22072016- Lyon, France- Flamel Technologies today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Monday, August 8, 2016, before the market open. About Flamel Technologies: Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulat
7/25/16 - SECFilings.com Covers Innovus Pharmaceuticals' Upcoming FDA Decision, Robust Portfolio, and Improved Cash Reserves and Financials
SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the release of an article discussing the current state of affairs and future outlook of Innovus Pharmaceuticals, Inc.. Innovus Pharmaceuticals is an emerging pharmaceutical company that delivers safe, innovative, and...
Articles(s): 1 - 16 of 16     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415